Nanoplatinates for Breast Cancer
Annual summary, 21 Sep 2009-20 Sep 2010
BRIGHAM AND WOMENS HOSPITAL BOSTON MA
Pagination or Media Count:
We demonstrate that the rational engineering of a polymer inspired by the bioactivation of cisplatin and oxaliplatin enables the engineering of a unique nanoplatinates, which improves antitumor efficacy of cisplatin by capitalizing on the inherent properties of nanoscale. This opens up the possibility to increase the maximal tolerated dose of cisplatin, which is an effective chemotherapeutic agent but dose limited due to nephrotoxicity. The clinical familiarity of using an established and globally used chemotherapeutic, together with the low cost of the basic building blocks used in fabricating the nanoparticle, can facilitate the rapid translation of this technology, thereby validating the potential of nanotechnology to impact global health. Additionally, we developed fullerenol as novel anti-angiogenic drug delivery vehicle, with its cisplatin conjugate showed improved antitumor efficacy by synergistic anti-angiogenic and anti-cancer activity.
- Medicine and Medical Research